Navigation Links
Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs
Date:11/4/2010

treated metastatic gastric cancer patients 128

SWOT analysis 128

Datamonitor drug assessment scorecard for Afinitor 129

Clinical and commercial attractiveness 130

If Phase III trial replicates Phase II survival, then Afinitor could become the standard of care in second-line metastatic gastric cancer 130

A relatively high rate of treatment discontinuation due to adverse events was seen in the Phase II study 130

Afinitor is set to be the first agent to reach the market for second-line metastatic gastric cancer 131

Afinitor shows applicability for use across the wider gastric cancer population 131

Design of the Phase III GRANITE-1 study may unnecessarily come under fire 131

Novartis's experience in the oncology market will prove crucial in ensuring Afinitor's success in gastric cancer 131

Satisfaction of unmet needs 131

Forecasts to 2019 132

Tykerb (lapatinib; GlaxoSmithKline) 133

Drug overview 133

Drug profile 133

Key historical events 134

Clinical trial data 135

Phase II results have shown minimal activity in first-line metastatic gastric cancer and failure to meet its primary endpoint of overall response rate 136

SWOT analysis 136

Datamonitor drug assessment scorecard for Tykerb 137

Clinical and commercial attractiveness 138

Minimal clinical data have been reported for Tykerb in gastric cancer, making it difficult to judge its clinical attractiveness 138

Dual inhibition of EGFR and HER-2 is a relatively new strategy in treatment of gastric cancer 139

Concerns exist over Tykerb's association with hepatotoxicity 139

Tykerb could provide strong competition to Herceptin in HER-2-positive gastric cancer 139

Satisfaction of unmet needs 139

Forecasts to 2019 140

Ramucirumab (IMC-1121B; Eli Lilly) 141

Drug overview 141

Drug profile 141

Key historical events 142

'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
2. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
3. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
4. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
5. Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports
6. Updated Pfizer Pipeline Focuses on Value, Unmet Medical Need
7. Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
8. Reportlinker Adds Prosthetic Heart Valves - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
9. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
10. Reportlinker Adds Interventional Cardiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
11. Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... N.J., July 30, 2015 PTC Therapeutics, Inc. ... and reported financial results for the second quarter ending ... on many fronts across the organization.  We are excited ... muscular dystrophy clinical trial ever conducted with topline results ... Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is ...
(Date:7/30/2015)... 30, 2015  Growth of the U.S. nonprescription market ... former prescription users to the OTC market. Due to ... robust Rx-to-OTC switch activity over the next five years ... many new brands entering the market into existing categories. ... five years (even those with low to moderate likelihood), ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Oct. 27 Pharmos Corporation (Pink Sheets: PARS ... nine-month period ended September 30, 2010. These results are included ... been filed with the SEC. During the quarter ... potential partners for Dextofisopam, its drug for irritable bowel syndrome ...
... N.J., Oct. 27 Systech International, innovator of ... Pac Automation, a leading supplier of end-of-line packaging ... integrated solution for global serialization requirements at Pack ... attendees have the opportunity to examine first hand ...
Cached Medicine Technology:Pharmos Corporation Reports 2010 Third Quarter Results 2Pharmos Corporation Reports 2010 Third Quarter Results 3Pharmos Corporation Reports 2010 Third Quarter Results 4Systech and Pester Pac Automation Exhibit Integrated Serialization Solution at Pack Expo 2010 2
(Date:8/1/2015)... In (PRWEB) , ... August 02, 2015 , ... ... month which will help the continuity of care for patients at this natural health ... of the unknown," Clinic Director Mary Heal said. "Heather's role is vital to our ...
(Date:8/1/2015)... , ... August 01, 2015 , ... The condition where ... both men and women often causing pain and discomfort. Those who spend a lot ... problem, and Northeast Houston Vein Center is doing what it can to create awareness ...
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... ... Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & Wellness ... into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was ... the latest and coolest applications on the market for iOS, Android, and Windows. Joe ... with viewers allows users to clarify, edit and delete any message including ones already ...
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
Breaking Medicine News(10 mins):Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... Six Million American Children of Healthcare Services, WASHINGTON, ... Psychiatry strongly urges Congress to override,President Bush,s veto of ... The House passed the S-CHIP bill by a 265-159 ... the President,s veto. The Senate passed the,measure by a ...
... Pam Brady,President of the California State PTA, ... federal legislation to expand the State,Children,s Health Insurance ... morning of legislation to expand the SCHIP,program is ... families,including approximately 800,000 in California, who need medical ...
... cosmetic dentist Dr. William,Hoskyns has joined the Atlanta Center ... Debra Gray King and her team at the Atlanta ... an international,reputation as the dentist to see for porcelain ... for his celebrity and high profile patients, Dr. Hoskyns ...
... JOSE, Calif., Oct. 3 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... the minimally invasive treatment of venous reflux disease, today,announced ... Small-Cap Growth,Stock Conference at 10:00 a.m. ET on October ... York, New York. An archive of the VNUS ...
... TORONTO, Oct. 3 /PRNewswire/ - Much controversy has ... potential complications of drug-eluting,heart stents, increasing the risk ... angioplasty procedure. However, a new Canadian study led ... and McMaster University,s Program for Assessment of Technologies ...
... Oct. 3 The American Health Information,Management ... ICD-10,implementation assessment and training consultation services for ... following AHIMA,s signing of,a contract with the ... contract requires AHIMA to determine ICD-10,s,impact(s) on ...
Cached Medicine News:Health News:American Academy of Child and Adolescent Psychiatry Reacts to S-CHIP Veto 2Health News:Prominent Cosmetic Dentist Dr. William Hoskyns Joins Leading Atlanta Practice 2Health News:New Canadian study finds drug coated heart stents to be safe: 2Health News:New Canadian study finds drug coated heart stents to be safe: 3Health News:New Canadian study finds drug coated heart stents to be safe: 4Health News:AHIMA Signs Contract With CMS for ICD-10 Implementation Assessment and Training 2
0.5 mm angled tip. Round knurled handle with dull finish. Tip angle: 150 degrees....
Angled for easy insertion into side port incision for manipulation of nucleus. Flat, paddle like tip for placement in groove to crack the nucleus for emulsification....
Angled shaft with 0.2 mm hourglass shape tip. Round knurled handle. Manufactured in titanium....
Ideal for nucleus manipulation during phacoemulsification. Also used for manipulating and rotating IOLs within the anterior chamber. Round knurled handle...
Medicine Products: